Xu Yuxi, Wang Xiaoqi, Hu Ziyi, Huang Ruihao, Yang Guancui, Wang Rui, Yang Shijie, Guo Liyan, Song Qingxiao, Wei Jin, Zhang Xi
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, 400037, China.
Department of Hematology, Affiliated Hospital of North Sichuan Medical College, Sichuan, 637000, China.
Heliyon. 2024 Oct 11;10(20):e39302. doi: 10.1016/j.heliyon.2024.e39302. eCollection 2024 Oct 30.
Autoimmune diseases (ADs) are a collection of immunological disorders in which the immune system responds to self-antigens by producing autoantibodies or self-sensitized cells. Current treatments are unable to cure ADs, and achieving long-term drug-free remission remains a challenging task. Hematopoietic stem cell transplantation (HSCT) stands out from other therapies by specifically targeting ADs that target various cell subpopulations, demonstrating notable therapeutic benefits and resulting in sustained drug-free remission. Since different ADs have distinct mechanisms of action, the comprehensive understanding of how HSCT works in treating ADs is crucial. This review provides a detailed overview of the latest research and clinical applications of HSCT in treating ADs, offering new insights for clinicians aiming to optimize its use for ADs management.
自身免疫性疾病（ADs）是一组免疫紊乱疾病，其中免疫系统通过产生自身抗体或自身致敏细胞对自身抗原作出反应。目前的治疗方法无法治愈ADs，实现长期无药缓解仍然是一项具有挑战性的任务。造血干细胞移植（HSCT）与其他疗法不同，它专门针对针对各种细胞亚群的ADs，显示出显著的治疗效果，并导致持续的无药缓解。由于不同的ADs有不同的作用机制，全面了解HSCT在治疗ADs中的作用至关重要。本综述详细概述了HSCT在治疗ADs方面的最新研究和临床应用，为旨在优化其在ADs管理中的应用的临床医生提供了新的见解。
